Medical Frontline Drug News
On January 5, CanSinoBIO announced that its self-developed "24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid)" has officially received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, with a registration classification of Preventive Biological Product Category 1.4.On January 6, Shanghai Aike 100 Biomedical Technology Co., Ltd. announced that the National Medical Products Administration (NMPA) of China had approved the new drug application for compound lisuride-piperacetazine hydrochloride capsules (Aizhida®) for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and above. Aizhida® is the world's first and currently the only compound formulation containing immediate-release d-piperacetazine hydrochloride (d-MPH) and prodrug lisuride-piperacetazine (SDX).Recently, XJN026 Nasal Spray, independently developed by Guangzhou New Can Biopharmaceutical Co., Ltd., has officially received clinical trial approval from the CDE. The indication is for the acute treatment of migraine attacks with or without aura in adults and children aged 6 to 17. This drug is classified as a Category 2.2改良型新药 (Modified New Drug).Recently, Beijing Xunsheng Biomedical Research Co., Ltd.'s HPV therapeutic vaccine successfully obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA), officially launching Phase I clinical trials. The HPV therapeutic vaccine is a therapeutic nucleic acid vaccine targeting high-risk HPV-16 and HPV-18.Investment and Financing in the Pharmaceutical Industry
On January 5, American biopharmaceutical giant Sanofi and AI-driven biotechnology company Earendil Labs (the overseas entity of Helixon) announced a deepened strategic partnership. This deal covers the development of bispecific antibodies across multiple autoimmune and inflammatory disease areas, with Sanofi leading the global clinical development and commercialization of the drug candidates. According to the agreement, Helixon will receive $160 million in upfront and near-term milestone payments, with the total potential value of the collaboration reaching $2.56 billion, setting a new record for the largest overseas licensing deal by a Chinese innovative pharmaceutical company.On December 31, Suzhou Zelgen Biologics announced a strategic collaboration and license option agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig). Under the agreement, AbbVie obtains exclusive rights to develop and commercialize ZG006 (Alveltamig) outside of Greater China (including mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region), while Zelgen retains the rights to develop and commercialize ZG006 in Greater China. Within Greater China, Zelgen will continue to lead the development of ZG006 until the completion of pivotal clinical trials and retain exclusive commercialization rights for ZG006 in this region.Technology-Driven Drug ResearchOn January 2, the team of Cao Yanan from Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine (Nan Jingmin, He Xianglong, and Liu Xiaoping as co-first authors of the paper), published a research article titled **Single-cell perturbations decipher ribosomal stress-surveillance regulators in type 2 diabetes** in the journal *Nature Metabolism*. The study utilized single-cell perturbation sequencing technology to systematically decode the functions of genes related to type 2 diabetes and insulin production in human pancreatic β cells.[1]Nan, J., He, X., Liu, X. et al. Single-cell perturbations decipher ribosomal stress-surveillance regulators in type 2 diabetes. Nat Metab (2026). https://doi.org/10.1038/s42255-025-01407-6
